Regenerative Medicine Specialsit Michael H. May Joins AgeX Board of Directors
7 August 2019 - - US-based biotechnology company AgeX Therapeutics, Inc. (NYSE American: AGE) has named Michael H. May, Ph.D to its board of directors, the company said.

May fills a recent vacancy on the board for an independent member, following the departure of Michael Mulroy, which was not because of a disagreement with AgeX on any matter relating to company operations, policies, or practices.

He is president and CEO of Canada's Centre for Commercialization of Regenerative Medicine, a leading and highly successful public-private partnership, which he has grown from inception to over 100 experts, and which under his leadership has raised over USD 100m, with spin-off companies and academic partners supported by CCRM securing an additional USD 750m.

Dr. May has extensive experience serving on a diverse range of company boards and industry-focused advisory committees, including at the International Society for Cell Therapy, the Alliance for Regenerative Medicine, and the International Society for Stem Cell Research (ISSCR). Dr. May holds a Ph.D. in Chemical Engineering from the University of Toronto.

AgeX Therapeutics is focused on developing and commercializing innovative therapeutics for human aging.

Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a whole host of diseases with a high unmet medical need.

AgeX has two preclinical cell therapy programmes: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.

AgeX's revolutionary longevity platform named induced Tissue Regeneration aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues.

AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeX's delivery technology to stably engraft PureStem cell therapies and slowly release iTR molecules in the body.

AgeX is developing its core product pipeline for use in the clinic to extend human healthspan, and is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications.